{"schema_version":"alpha-governance-record-v2","alpha_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce","ontology_version":"alpha-governance-ontology-v1","as_of":"2026-10-17T19:35:07.291571+00:00","published_at":"2026-10-17T04:47:19.235235+00:00","section":"relationships","data":{"state":"PUBLISHED","relationships":[{"relationship_id":"alpha:relationship:seat_on:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:5:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"seat_on","from_id":"alpha:person:adi-mor","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Adi Mor","to_label":"Chemomab Therapeutics Ltd.","valid_from":"2021-01-01","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:5","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"]},{"relationship_id":"alpha:relationship:seat_on:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:6:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"seat_on","from_id":"alpha:person:alan-moses","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Alan Moses","to_label":"Chemomab Therapeutics Ltd.","valid_from":"2021-01-01","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:6","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"]},{"relationship_id":"alpha:relationship:seat_on:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:7:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"seat_on","from_id":"alpha:person:claude-nicaise","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Claude Nicaise","to_label":"Chemomab Therapeutics Ltd.","valid_from":"2021-01-01","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:7","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"]},{"relationship_id":"alpha:relationship:seat_on:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:8:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"seat_on","from_id":"alpha:person:dale-pfost","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Dale Pfost","to_label":"Chemomab Therapeutics Ltd.","valid_from":"2021-01-01","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:8","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"]},{"relationship_id":"alpha:relationship:seat_on:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"seat_on","from_id":"alpha:person:joel-maryles","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Joel Maryles","to_label":"Chemomab Therapeutics Ltd.","valid_from":"2021-01-01","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"]},{"relationship_id":"alpha:relationship:seat_on:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"seat_on","from_id":"alpha:person:neil-cohen","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Neil Cohen","to_label":"Chemomab Therapeutics Ltd.","valid_from":"2020-01-01","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"]},{"relationship_id":"alpha:relationship:seat_on:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"seat_on","from_id":"alpha:person:nissim-darvish","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Nissim Darvish","to_label":"Chemomab Therapeutics Ltd.","valid_from":"2021-01-01","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"]},{"relationship_id":"alpha:relationship:committee_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:16:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"committee_of","from_id":"alpha:committee:chemomab-therapeutics-ltd:audit","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Audit","to_label":"Chemomab Therapeutics Ltd.","valid_from":null,"valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:16","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5","alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"]},{"relationship_id":"alpha:relationship:chairs:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:16:committee:chemomab-therapeutics-ltd:audit","relationship_type":"chairs","from_id":"alpha:person:joel-maryles","to_id":"alpha:committee:chemomab-therapeutics-ltd:audit","from_label":"Joel Maryles","to_label":"Audit","valid_from":null,"valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:16","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"]},{"relationship_id":"alpha:relationship:member_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:16:committee:chemomab-therapeutics-ltd:audit","relationship_type":"member_of","from_id":"alpha:person:alan-moses","to_id":"alpha:committee:chemomab-therapeutics-ltd:audit","from_label":"Alan Moses","to_label":"Audit","valid_from":"2021-01-01","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:16","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"]},{"relationship_id":"alpha:relationship:committee_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"committee_of","from_id":"alpha:committee:chemomab-therapeutics-ltd:audit-chair-nominating-and-governance","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Audit · Chair; Nominating and Governance","to_label":"Chemomab Therapeutics Ltd.","valid_from":"2021-01-01","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"]},{"relationship_id":"alpha:relationship:member_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9:committee:chemomab-therapeutics-ltd:audit-chair-nominating-and-governance","relationship_type":"member_of","from_id":"alpha:person:joel-maryles","to_id":"alpha:committee:chemomab-therapeutics-ltd:audit-chair-nominating-and-governance","from_label":"Joel Maryles","to_label":"Audit · Chair; Nominating and Governance","valid_from":"2021-01-01","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"]},{"relationship_id":"alpha:relationship:committee_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:20:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"committee_of","from_id":"alpha:committee:chemomab-therapeutics-ltd:compensation","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Compensation","to_label":"Chemomab Therapeutics Ltd.","valid_from":null,"valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:20","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"]},{"relationship_id":"alpha:relationship:chairs:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:20:committee:chemomab-therapeutics-ltd:compensation","relationship_type":"chairs","from_id":"alpha:person:nissim-darvish","to_id":"alpha:committee:chemomab-therapeutics-ltd:compensation","from_label":"Nissim Darvish","to_label":"Compensation","valid_from":null,"valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:20","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"]},{"relationship_id":"alpha:relationship:member_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:20:committee:chemomab-therapeutics-ltd:compensation","relationship_type":"member_of","from_id":"alpha:person:neil-cohen","to_id":"alpha:committee:chemomab-therapeutics-ltd:compensation","from_label":"Neil Cohen","to_label":"Compensation","valid_from":null,"valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:20","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"]},{"relationship_id":"alpha:relationship:committee_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"committee_of","from_id":"alpha:committee:chemomab-therapeutics-ltd:compensation-chair","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Compensation · Chair","to_label":"Chemomab Therapeutics Ltd.","valid_from":"2021-01-01","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"]},{"relationship_id":"alpha:relationship:member_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11:committee:chemomab-therapeutics-ltd:compensation-chair","relationship_type":"member_of","from_id":"alpha:person:nissim-darvish","to_id":"alpha:committee:chemomab-therapeutics-ltd:compensation-chair","from_label":"Nissim Darvish","to_label":"Compensation · Chair","valid_from":"2021-01-01","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"]},{"relationship_id":"alpha:relationship:committee_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"committee_of","from_id":"alpha:committee:chemomab-therapeutics-ltd:compensation-nominating-and-governance-chair","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Compensation; Nominating and Governance · Chair","to_label":"Chemomab Therapeutics Ltd.","valid_from":"2020-01-01","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"]},{"relationship_id":"alpha:relationship:member_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10:committee:chemomab-therapeutics-ltd:compensation-nominating-and-governance-chair","relationship_type":"member_of","from_id":"alpha:person:neil-cohen","to_id":"alpha:committee:chemomab-therapeutics-ltd:compensation-nominating-and-governance-chair","from_label":"Neil Cohen","to_label":"Compensation; Nominating and Governance · Chair","valid_from":"2020-01-01","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10","evidence_ids":["alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6"]},{"relationship_id":"alpha:relationship:committee_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:23:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"committee_of","from_id":"alpha:committee:chemomab-therapeutics-ltd:nominating-and-governance","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Nominating and Governance","to_label":"Chemomab Therapeutics Ltd.","valid_from":null,"valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:23","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"]},{"relationship_id":"alpha:relationship:chairs:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:23:committee:chemomab-therapeutics-ltd:nominating-and-governance","relationship_type":"chairs","from_id":"alpha:person:neil-cohen","to_id":"alpha:committee:chemomab-therapeutics-ltd:nominating-and-governance","from_label":"Neil Cohen","to_label":"Nominating and Governance","valid_from":null,"valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:23","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"]},{"relationship_id":"alpha:relationship:member_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:23:committee:chemomab-therapeutics-ltd:nominating-and-governance","relationship_type":"member_of","from_id":"alpha:person:joel-maryles","to_id":"alpha:committee:chemomab-therapeutics-ltd:nominating-and-governance","from_label":"Joel Maryles","to_label":"Nominating and Governance","valid_from":null,"valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:23","evidence_ids":["alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5"]},{"relationship_id":"alpha:relationship:executive_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:12:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"executive_of","from_id":"alpha:person:adi-mor","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Adi Mor","to_label":"Chemomab Therapeutics Ltd.","valid_from":"2023-03-20","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:12","evidence_ids":["alpha:projection-evidence:document:0a6d88181566fb91facd65dc58b3461619162eb54f8c01be221d2b9aeabe7eaa"]},{"relationship_id":"alpha:relationship:executive_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:13:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"executive_of","from_id":"alpha:person:dale-pfost","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Dale Pfost","to_label":"Chemomab Therapeutics Ltd.","valid_from":"2023-03-20","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:13","evidence_ids":["alpha:projection-evidence:document:d67e834750540b5de9e616c9c2a989cf3d671dd1f9b63af3421b8249e7bd9d74"]},{"relationship_id":"alpha:relationship:executive_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:14:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"executive_of","from_id":"alpha:person:donald-marvin","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Donald Marvin","to_label":"Chemomab Therapeutics Ltd.","valid_from":"2023-03-20","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:14","evidence_ids":["alpha:projection-evidence:document:30f078484ad42b7db98ae5d0f839c499b23a33b798561c25cfdc4096ba0547af"]},{"relationship_id":"alpha:relationship:executive_of:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:15:company:b1855362-5134-4427-ae32-49edcf67e58e","relationship_type":"executive_of","from_id":"alpha:person:matthew-frankel","to_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","from_label":"Matthew Frankel","to_label":"Chemomab Therapeutics Ltd.","valid_from":"2023-03-20","valid_to":null,"lifecycle_state":"active","claim_id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:15","evidence_ids":["alpha:projection-evidence:document:12af43a6bb01e3773f017b270e7f79aeb9ab8eed80b489139819eab26a9dab3f"]}]},"claims":[{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:5","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:adi-mor","object_label":"Adi Mor","object_source_name_forms":[],"value":"Adi Mor: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:adi-mor","name":"Adi Mor"},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2022-04-28","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:6","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:alan-moses","object_label":"Alan Moses","object_source_name_forms":[],"value":"Alan Moses: Director, Audit","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:alan-moses","name":"Alan Moses"},"title":"Director","role_category":"director","committee":"Audit","is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2022-04-28","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:7","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:claude-nicaise","object_label":"Claude Nicaise","object_source_name_forms":[],"value":"Claude Nicaise: Director, Audit","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:claude-nicaise","name":"Claude Nicaise"},"title":"Director","role_category":"director","committee":"Audit","is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2022-04-28","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:8","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:dale-pfost","object_label":"Dale Pfost","object_source_name_forms":[],"value":"Dale Pfost: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:dale-pfost","name":"Dale Pfost"},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2022-04-28","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:9","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:joel-maryles","object_label":"Joel Maryles","object_source_name_forms":[],"value":"Joel Maryles: Director, Audit · Chair; Nominating and Governance","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:joel-maryles","name":"Joel Maryles"},"title":"Director","role_category":"director","committee":"Audit · Chair; Nominating and Governance","is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2022-04-28","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:10","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:neil-cohen","object_label":"Neil Cohen","object_source_name_forms":[],"value":"Neil Cohen: Director, Compensation; Nominating and Governance · Chair","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:neil-cohen","name":"Neil Cohen"},"title":"Director","role_category":"director","committee":"Compensation; Nominating and Governance · Chair","is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2022-04-28","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:11","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:nissim-darvish","object_label":"Nissim Darvish","object_source_name_forms":[],"value":"Nissim Darvish: Director, Compensation · Chair","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:nissim-darvish","name":"Nissim Darvish"},"title":"Director","role_category":"director","committee":"Compensation · Chair","is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2021-01-01","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2022-04-28","effective_from":"2021-01-01","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:12","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:adi-mor","object_label":"Adi Mor","object_source_name_forms":[],"value":"Adi Mor: Director, Chief Scientific Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:adi-mor","name":"Adi Mor"},"title":"Director, Chief Scientific Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2023-03-20","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2023-03-20","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:0a6d88181566fb91facd65dc58b3461619162eb54f8c01be221d2b9aeabe7eaa","identity_scope":"source_document_reference","source_type":"sec_filing","title":"CMMB 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/zk2329403.htm","source_date":"2023-03-20T00:00:00+00:00","retrieved_at":"2026-05-16T00:42:44.669408+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2023-03-20T00:00:00+00:00","effective_from":"2023-03-20","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:13","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:dale-pfost","object_label":"Dale Pfost","object_source_name_forms":[],"value":"Dale Pfost: Chairman of the Board, Chief Executive Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:dale-pfost","name":"Dale Pfost"},"title":"Chairman of the Board, Chief Executive Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2023-03-20","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2023-03-20","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:d67e834750540b5de9e616c9c2a989cf3d671dd1f9b63af3421b8249e7bd9d74","identity_scope":"source_document_reference","source_type":"sec_filing","title":"CMMB 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/zk2329403.htm","source_date":"2023-03-20T00:00:00+00:00","retrieved_at":"2026-05-16T00:42:43.792025+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2023-03-20T00:00:00+00:00","effective_from":"2023-03-20","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:14","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:donald-marvin","object_label":"Donald Marvin","object_source_name_forms":[],"value":"Donald Marvin: Chief Financial Officer, Executive Vice President and Chief Operating Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:donald-marvin","name":"Donald Marvin"},"title":"Chief Financial Officer, Executive Vice President and Chief Operating Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2023-03-20","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2023-03-20","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:30f078484ad42b7db98ae5d0f839c499b23a33b798561c25cfdc4096ba0547af","identity_scope":"source_document_reference","source_type":"sec_filing","title":"CMMB 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/zk2329403.htm","source_date":"2023-03-20T00:00:00+00:00","retrieved_at":"2026-05-16T00:42:44.296733+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2023-03-20T00:00:00+00:00","effective_from":"2023-03-20","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:leadership_role:15","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:matthew-frankel","object_label":"Matthew Frankel","object_source_name_forms":[],"value":"Matthew Frankel: Chief Medical Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:matthew-frankel","name":"Matthew Frankel"},"title":"Chief Medical Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2023-03-20","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2023-03-20","valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:document:12af43a6bb01e3773f017b270e7f79aeb9ab8eed80b489139819eab26a9dab3f","identity_scope":"source_document_reference","source_type":"sec_filing","title":"CMMB 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/zk2329403.htm","source_date":"2023-03-20T00:00:00+00:00","retrieved_at":"2026-05-16T00:42:45.206879+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2023-03-20T00:00:00+00:00","effective_from":"2023-03-20","effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:16","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardCommittee","object_id":null,"object_label":null,"object_source_name_forms":[],"value":"Audit: Chair Joel Maryles; Members Joel Maryles (Chair); Alan Moses; Claude Nicaise","claim_type":"committee_record","predicate_id":"alpha:predicate:committee_record","predicate_version":1,"machine_key":"committee_record","human_label":"Committee Record","governed_predicate":true,"machine_value":{"name":"Audit","canonical_type":"audit","chair":"Joel Maryles","members":[{"display_name":"Joel Maryles","person_slug":"joel-maryles","is_chair":true},{"display_name":"Alan Moses","person_slug":"alan-moses","is_chair":false},{"display_name":"Claude Nicaise","person_slug":"claude-nicaise","is_chair":false}],"source_id":"board_seats"},"corroboration_count":1,"source_claim_count":1,"valid_from":null,"valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":null,"effective_from":null,"effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"source_reported","review_state":"none","confidence":null,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:20","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardCommittee","object_id":null,"object_label":null,"object_source_name_forms":[],"value":"Compensation: Chair Nissim Darvish; Members Nissim Darvish (Chair); Neil Cohen","claim_type":"committee_record","predicate_id":"alpha:predicate:committee_record","predicate_version":1,"machine_key":"committee_record","human_label":"Committee Record","governed_predicate":true,"machine_value":{"name":"Compensation","canonical_type":"compensation","chair":"Nissim Darvish","members":[{"display_name":"Nissim Darvish","person_slug":"nissim-darvish","is_chair":true},{"display_name":"Neil Cohen","person_slug":"neil-cohen","is_chair":false}],"source_id":"board_seats"},"corroboration_count":1,"source_claim_count":1,"valid_from":null,"valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":null,"effective_from":null,"effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"source_reported","review_state":"none","confidence":null,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:b1855362-5134-4427-ae32-49edcf67e58e:committee_record:23","subject_id":"alpha:company:b1855362-5134-4427-ae32-49edcf67e58e","predicate":"alpha:hasBoardCommittee","object_id":null,"object_label":null,"object_source_name_forms":[],"value":"Nominating and Governance: Chair Neil Cohen; Members Neil Cohen (Chair); Joel Maryles","claim_type":"committee_record","predicate_id":"alpha:predicate:committee_record","predicate_version":1,"machine_key":"committee_record","human_label":"Committee Record","governed_predicate":true,"machine_value":{"name":"Nominating and Governance","canonical_type":"nominating_governance","chair":"Neil Cohen","members":[{"display_name":"Neil Cohen","person_slug":"neil-cohen","is_chair":true},{"display_name":"Joel Maryles","person_slug":"joel-maryles","is_chair":false}],"source_id":"board_seats"},"corroboration_count":1,"source_claim_count":1,"valid_from":null,"valid_to":null,"recorded_at":"2026-10-17T04:47:19.235235+00:00","sources":[{"id":"alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":null,"effective_from":null,"effective_until":null,"observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"source_reported","review_state":"none","confidence":null,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"}],"evidence":[{"id":"alpha:projection-evidence:document:f8130897f9cf0d732e1da38a6ae3010fda702ced1002d8a1d67e778e6cf1b9f6","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Chemomab Therapeutics Ltd. DEF 14A 2022-04-28","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":"2022-04-28","retrieved_at":"2026-04-29T00:04:01.902+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:0a6d88181566fb91facd65dc58b3461619162eb54f8c01be221d2b9aeabe7eaa","identity_scope":"source_document_reference","source_type":"sec_filing","title":"CMMB 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/zk2329403.htm","source_date":"2023-03-20T00:00:00+00:00","retrieved_at":"2026-05-16T00:42:44.669408+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:d67e834750540b5de9e616c9c2a989cf3d671dd1f9b63af3421b8249e7bd9d74","identity_scope":"source_document_reference","source_type":"sec_filing","title":"CMMB 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/zk2329403.htm","source_date":"2023-03-20T00:00:00+00:00","retrieved_at":"2026-05-16T00:42:43.792025+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:30f078484ad42b7db98ae5d0f839c499b23a33b798561c25cfdc4096ba0547af","identity_scope":"source_document_reference","source_type":"sec_filing","title":"CMMB 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/zk2329403.htm","source_date":"2023-03-20T00:00:00+00:00","retrieved_at":"2026-05-16T00:42:44.296733+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:12af43a6bb01e3773f017b270e7f79aeb9ab8eed80b489139819eab26a9dab3f","identity_scope":"source_document_reference","source_type":"sec_filing","title":"CMMB 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891323001041/zk2329403.htm","source_date":"2023-03-20T00:00:00+00:00","retrieved_at":"2026-05-16T00:42:45.206879+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:1c7cdb624f8e48686715379deffefecf885345b9a5837589843008a2fe4614e5","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1534248/000117891322001678/zk2227688.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"coverage_state":"PUBLISHED","quality":{"schema_version":"alpha-record-quality-v2","overall":0.84,"status":"strong","publication_readiness":"ready","dimensions":{"identity":1,"coverage":0.5,"freshness":1,"evidence_completeness":1,"source_authority":0.896,"cross_source_agreement":0.75,"temporal_completeness":0.611},"diagnostics":{"published_claims":25,"factual_claims":25,"claims_with_linked_evidence":25,"disputed_claims":0,"conflicts":0,"stale_claims":0,"stale_claim_ids":[],"temporal_claims":18,"temporal_claims_with_valid_from":11,"missing_coverage_sections":["governance","financials","workforce","ownership","ratings"],"missing_expected_claims":["headquarters","official_website","financial_metric","governance_document","ownership","auditor","legal_matter","risk","ai_governance"]},"derivation":"deterministic_record_projection"},"publication":{"state":"PUBLISHED","published_at":"2026-10-17T04:47:19.235235+00:00","observed_at":"2026-10-17T04:47:19.235235+00:00","reviewed_at":"2026-10-17T04:47:19.235235+00:00","verified_at":"2026-10-17T04:47:19.235235+00:00"},"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":25,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed.","facets":[{"facet":"identity","state":"unclaimed"},{"facet":"evidence","state":"source_reported"},{"facet":"evaluation","state":"not_evaluated"},{"facet":"monitoring","state":null},{"facet":"authority","state":null},{"facet":"freshness","state":"current"}]},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"},"resource":{"uri":"alpha://company/chemomab-therapeutics-ltd/relationships","section":"relationships","href":"https://registry.alpha.ac/api/public/companies/chemomab-therapeutics-ltd?format=record&section=relationships","media_type":"application/json","availability":"contract"},"limitations":["Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."]}